A detailed history of Portolan Capital Management, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Portolan Capital Management, LLC holds 179,634 shares of MYGN stock, worth $2.4 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares
179,634
Holding current value
$2.4 Million
% of portfolio
0.39%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.97 - $28.6 $4.31 Million - $5.14 Million
179,634 New
179,634 $4.92 Million
Q2 2019

Aug 14, 2019

SELL
$22.67 - $35.0 $2.85 Million - $4.39 Million
-125,532 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$26.93 - $34.7 $3.38 Million - $4.36 Million
125,532 New
125,532 $4.17 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.08B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Portolan Capital Management, LLC Portfolio

Follow Portolan Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Portolan Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Portolan Capital Management, LLC with notifications on news.